氯吡格雷联合阿托伐他汀或瑞舒伐他汀用于脑梗死二级预防效果比较

发布时间：2018-06-22 23:18

本文选题：脑梗死 + 阿托伐他汀　；参考：《山东医药》2017年12期

【摘要】：目的探讨氯吡格雷联合阿托伐他汀或瑞舒伐他汀用于脑梗死二级预防的效果。方法选取行二级预防的脑梗死患者150例,随机分为阿托伐他汀组、瑞舒伐他汀组,每组75例。两组均给予氯吡格雷治疗,阿托伐他汀组加用阿托伐他汀,瑞舒伐他汀组加用瑞舒伐他汀,均连续给药24周。两组于治疗前及治疗1、12、24周检测血清TG、TC、LDL-C及血小板聚集率,记录两组治疗期间心肌酶升高和肝功能损伤发生率;随访1年,记录脑梗死复发率。结果两组治疗1、12、24周时血清TC、TG、LDL-C水平及血小板聚集率均低于治疗前(P均0.05),各时间点比较差异均无统计学意义(P均0.05)。阿托伐他汀组及瑞舒伐他汀组治疗期间心肌酶升高发生率分别为5.33%、2.67%,肝功能损伤发生率分别为2.67%、1.33%,组间比较P均0.05。两组均完成1年随访,阿托伐他汀组及瑞舒伐他汀组脑梗死复发率分别为10.67%、8.00%,组间比较P0.05。结论氯吡格雷联合阿托伐他汀或瑞舒伐他汀治疗脑梗死的效果及安全性均较好,且两种方法的效果及安全性比较无明显差异。
[Abstract]:Objective to investigate the effect of clopidogrel combined with Atto vastatin or resuvastatin on the secondary prevention of cerebral infarction. Methods one hundred and fifty patients with secondary cerebral infarction were randomly divided into Atto vastatin group and resuvastatin group with 75 cases in each group. Both groups were treated with clopidogrel, Atto vastatin plus Atto vastatin and resuvastatin plus resuvastatin for 24 weeks. The serum TGV TCU LDL-C and platelet aggregation rate were measured before and 24 weeks after treatment in both groups, and the incidence of myocardial enzymes and liver function injury were recorded during the treatment, and the recurrence rate of cerebral infarction was recorded after 1 year follow up. Results at 24 weeks after treatment, the level of serum TCU TGG LDL-C and platelet aggregation rate in the two groups were lower than those before treatment (P 0.05), and there was no significant difference between the two groups at each time point (P 0.05). The incidence of myocardial enzyme elevation and liver function injury in Atto and rosuvastatin groups were 5.33 and 2.67, respectively, and the incidence of liver function injury was 2.67 and 1.33, respectively (P < 0.05). The recurrence rate of cerebral infarction in Atto vastatin group and resuvastatin group was 10.67 and 8.00, respectively, with a comparison between the two groups (P0.05). Conclusion Clopidogrel combined with Atto vastatin or rosuvastatin is effective and safe in the treatment of cerebral infarction, and there is no significant difference between the two methods.
【作者单位】：天门市第一人民医院;华中科技大学同济医学院附属同济医院;
【分类号】：R743.33

【相似文献】